Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

Bayer faces second trial over alleged Roundup cancer risk

Reprints
Roundup weedkiller

(Reuters) — Bayer AG is set to face a second U.S. jury over allegations that its popular glyphosate-based weed killer Roundup causes cancer, six months after the company’s share price was rocked by a $289 million verdict in California state court.

A lawsuit by California resident Edwin Hardeman against the company was scheduled to begin on Monday in federal rather than state court. The trial is also a test case for a larger litigation. More than 760 of the 9,300 Roundup cases nationwide are consolidated in the federal court in San Francisco that is hearing Mr. Hardeman’s case.

Bayer denies all allegations that Roundup or glyphosate causes cancer, saying decades of independent studies have shown the world’s most widely used weedkiller to be safe for human use and noting that regulators around the world have approved the product.

Under a January ruling by U.S. District Judge Vince Chhabria, who presides over the federal litigation, jurors in Mr. Hardeman’s case will not initially hear all the evidence presented in last year’s California trial.

Judge Chhabria called evidence by plaintiffs that the company allegedly attempted to influence regulators and manipulate public opinion “a distraction” from the science in the cases. He said such evidence should only go before the jury in a second trial phase that would only take place if they determined Roundup caused Mr. Hardeman’s cancer.

Evidence of corporate misconduct was seen as playing a key role in the finding by a California state court jury in August that Roundup caused another man’s non-Hodgkin’s lymphoma and that Bayer’s Monsanto unit failed to warn consumers about the weed killer’s cancer risks. That jury’s $289 million damages award was later reduced to $78 million.

Bayer’s share price dropped 10% following the verdict and has remained volatile.

Mr. Hardeman began using the Roundup brand herbicide with glyphosate in the 1980s to control poison oak and weeds on his property and sprayed “large volumes” of the chemical for many years on a regular basis, according to court documents. He was diagnosed with non-Hodgkin’s lymphoma, a cancer of the lymph system, in February 2015 and filed his lawsuit a year later.

But Mr. Hardeman has a history of hepatitis C, a risk factor for developing lymphoma. Bayer in court filings also said the majority of non-Hodgkin’s lymphoma incidents are idiopathic, or have no known cause.

Plaintiffs criticized Judge Chhabria’s order dividing the trial and restricting evidence as “unfair,” saying their scientific evidence allegedly showing glyphosate causes cancer is inextricably linked to Monsanto’s alleged wrongful conduct.

 

Read Next

  • Bayer shares plummet after Monsanto's Roundup cancer trial

    (Reuters) – Bayer A.G. shares plunged more than 10% on Monday after a California jury ordered the German company’s newly acquired Monsanto subsidiary to pay $289 million for not warning of cancer risks posed by its main weed killer.